Human Metabolome Technologies, Inc. (6090)

Market cap
¥3.7B
P/E ratio
17.3x
Provides high-sensitivity analysis of metabolic compounds to pharmaceutical companies, research institutions, and manufacturers to support drug development and product testing.
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Jun 30, 202516-32.86%
Jun 30, 202424-6.97%
Jun 30, 202326-28.29%
Jun 30, 202236-21.53%
Jun 30, 202146+100.77%
Jun 30, 202023-38.38%
Jun 30, 201937-6.36%
Mar 31, 201939-15.31%
Mar 31, 201847+172.24%
Mar 31, 201717-33.59%
Mar 31, 201626-52.79%
Mar 31, 201555
AI Chat